Erratum to: From cell senescence to age-related diseases: differential mechanisms of action of senescence-associated secretory phenotypes

Hae-Ok Byun^{1,2}, Young-Kyoung Lee^{1,2}, Jeong-Min Kim^{1,3} & Gyesoon Yoon^{1,2,*}

¹Department of Biochemistry, Ajou University School of Medicine, ²Department of Biomedical Science, Graduate School, ³College of Natural Sciences, Ajou University, Suwon 16499, Korea

BMB Rep. 2015; 48(10): 549-558, PMID: 26129674

The BMB Reports would like to correct in the reference of BMB Rep. 48(10), 549-558 titled "From cell senescence to age-related diseases: differential mechanisms of action of senescence-associated secretory phenotypes". The REFERENCE should be corrected as red highlighting in this pages. This Erratum's doi is <https://doi.org/10.5483/BMBRep.2016.49.11.122>.

Cellular senescence is a process by which cells enter a state of permanent cell cycle arrest. It is commonly believed to underlie organismal aging and age-associated diseases. However, the mechanism by which cellular senescence contributes to aging and age-associated pathologies remains unclear. Recent studies showed that senescent cells exert detrimental effects on the tissue microenvironment, generating pathological facilitators or aggravators. The most significant environmental effector resulting from senescent cells is the senescence-associated secretory phenotype (SASP), which is constituted by a strikingly increased expression and secretion of diverse pro-inflammatory cytokines. Careful investigation into the components of SASPs and their mechanism of action, may improve our understanding of the pathological backgrounds of age-associated diseases. In this review, we focus on the differential expression of SASP-related genes, in addition to SASP components, during the progress of senescence. We also provide a perspective on the possible action mechanisms of SASP components, and potential contributions of SASP-expressing senescent cells, to age-associated pathologies.

INTRODUCTION

Cellular senescence is causally implicated in biological aging;

*Corresponding author. Tel: +82-31-219-5054; Fax: +82-31-219-5059; E-mail: ypeace@ajou.ac.kr

Received 23 June 2015

Keywords: Age-associated diseases, Cell senescence, Differential expression, Senescence-associated secretory phenotypes (SASP)

there is evidence of accumulated senescent cells in tissues of chronologically aging organisms (1-3). In addition, potential links between cellular senescence and age-related diseases, including osteoarthritis (4) and atherosclerosis (5), Parkinson's disease (6), and cancer (7), have been reported and are supported by a recent report that removal of senescent cells can prevent or delay tissue dysfunction and extend the "healthspan" (8).

Cellular senescence refers to a permanently arrested state of cell growth that displays unresponsiveness to growth factors. It was originally described in terms of exhaustion of the replicative capacity of cultured primary fibroblasts (3) and was thought to be due in part to telomere attrition (the gradual loss of DNA at the ends of chromosomes that accompanies continuous cell division) (9, 10). It has been shown that telomere attrition generates a persistent DNA damage response, which initiates and maintains senescent growth arrest (10-12). However, cell senescence can also be induced by various stresses, including oncogenic activation, UV radiation, and chemical damage or therapeutic drug toxicity (13-15). The often unspecified causes and unclear molecular mechanisms of senescence provokes one of the fundamental questions in the biology of aging and clinical geriatrics: how does cellular senescence contribute to age-related diseases?

Despite the different causes of senescence, the senescent cells display several prominent common phenotypes, in addition to irreversible growth arrest and unresponsiveness to growth factors. Major representative phenotypes are an enlarged and flat cellular morphology with intracellular mass increase (16); increased reactive oxygen species (ROS) production and accumulation of consequent ROS-mediated damage products (17, 18); acquisition of senescence-associated β -galactosidase activity (SA- β -gal) (19); a discernible change in chromatin organization known as senescence-associated heterochromatin

foci formation (SAHF) (20, 21); and acquisition of the senescence-associated secretory phenotype (SASP), which includes secreted inflammatory, growth-regulating, and tissue-remodeling factors (22, 23). Although these phenotypic changes are often used as indications for cellular senescence, their association to each other and their exact relevance to senescence itself, organismal aging, and age-related diseases, are not clearly understood. One established senescent feature linked to age-related pathologies is the fact that senescent cells lose their proliferation capacity and consequent normal cell turnover, thereby weakening tissue repair and regeneration, and leading to decrements in function (24). Another feature recently drawing attention is the release of SASPs which, due to their potent autocrine and paracrine activities, control the functions and activities of the surrounding cells and also modify the extracellular microenvironments (22, 23). However, senescent cells express and release a variety of SASP components, with different levels of individual SASP components at different stages of senescent progress (25); thus, it is quite difficult to unravel the link between individual and combined SASP components and age-related pathologies.

Before discussing the action modes of SASP components, several salient features need to be mentioned. First, there are many types of SASP components, such as cytokines, chemokines, growth factors, and proteases, which are expressed and involved in senescence at different individual levels. This indicates that the overall contribution to a specific pathogenesis of the combined actions of all SASP components may be quite different from the known effects of individual SASP components. Second, the senescent cells also express and release regulatory or inhibitory factors, such as tissue inhibitors of metalloproteinases (TIMPs), plasminogen activator inhibitors (PAI), and insulin-like growth factor-binding proteins (IGFBPs). This implies that the ultimate activity of a single SASP component may not be determined only by the number of SASP components involved, but also by the combinatorial action of the SASP components along with their regulatory factors. Third, the progress of senescence alters the expression levels of SASP receptors, modifying cellular reactivity to specific SASP ligands. Fourth, the types and levels of SASP components vary among the stages of senescence progression, suggesting that senescent cells at different stages may affect the age-related pathogenesis differently. Therefore, careful consideration of the altered expression profiles of individual SASP components and their associated regulatory factors and receptors may allow us to hypothesize the possible mechanism of action by which individual SASP components modulate the surrounding tissue microenvironment, and to determine how senescent cells communicate with the surrounding cells.

In this review, we discuss various studies relating to the secretion of SASP components from senescent cells and their involvement in age-related pathologies. Here, the aforementioned features of SASP components and their associated gene products are collectively referred to as SASP-related factors. We al-

so consider the possible action mechanisms of individual SASP components on the tissue microenvironment, and finally propose the potential contributions of senescent cells to senescence-related pathologies.

SPECIFIC VERSUS OVERALL GENE EXPRESSION CHANGES IN SENESCENCE

Cell size is fairly homogeneous during the early passages of human fetal fibroblasts, while cell size at the terminal stages (senescence) of the *in vitro* cellular life span is large and heterogeneous (26, 27). Similarly, increases in cell size (surface area) and cell mass (components) are generally seen in most cases of cellular senescence triggered by various stresses. Thus, this enlarged cell morphology and size is the most prominent senescent phenotype, which allows us to judge, by appearance, whether or not cells are progressing to senescence. How, then, do senescent cells acquire this phenotype? The enlarged cell size reflects an increase in cell mass, generally in terms of both molecular and organellar components (28-30). However, it is unclear whether the increase in mass is confined to specific cellular molecules and compartments, or whether it is caused by a random and uncontrolled increase.

The majority of senescent cells are in the G₁ phase of the cell cycle (i.e., G₁, S, G₂, and M phase, respectively), with an overall delay seen in cell cycle progression, indicating that the G₁ checkpoints are critical controls for senescence (31, 32). This stable G₁ arrest is mainly executed by an interplay between the Rb and p53 tumor suppressor pathways (33, 34). Senescent cells express activated p53 transcription factor (35) and, consequently, elevated levels of p21^{Cip1/Waf1} (36), p15^{INK4b} (37, 38), and p16^{INK4a} (39); also, they are unable to hyperphosphorylate Rb protein in response to mitogenic stimulation (40). Activation of these cell cycle checkpoints comprises an important mechanism of cell cycle arrest in senescent cells (41). However, G₁ is the phase at which the cell grows in size by synthesizing the mRNA and proteins required for cell components, as well as some specific proteins required for DNA synthesis. Once the required cell growth and mass increase has taken place, the cell enters the next phase of the cell cycle, the S phase. Senescent cells in G₁ arrest, which is the result of an inability to transition from G₁ to S without the cessation of synthesis of cellular molecules and components, may result in enlarged cell morphology. Ultimately, this representative senescent phenotype, i.e. progressive enlargement of cell morphology, is tightly linked with another well-known senescent feature: senescent cells remain metabolically active, which includes an overall increase in gene expression (42), despite the loss of their replicative capacity.

Enhanced protein synthesis during senescent arrest is maintained by mTOR activation and upregulated activity of phosphatidylinositol 3-kinase (PI3K), an upstream activator of mTOR (43-45). Moreover, GSK3-mediated augmentation of lipogenesis and glycogenesis has been reported to be critically linked

with an increase in the overall mass of organelles (such as mitochondria, lysosome, Golgi, and ER) and cell granularity (46, 47). In particular, increased mass of lysosomes and mitochondria has been observed in both senescent cells and aged tissues (30, 48, 49). The combined activity of augmented lipogenesis and protein synthesis leads to the increase in organellar formation. However, the imbalance between anabolic activities, including protein synthesis and organellar biogenesis, and cell cycle progression contributes to the abnormal cell volume increase.

Alongside the overall increased synthesis of mRNAs and proteins, the senescent cells also have an extremely altered expression of specific genes, that are often referred to as senescence-associated genes. These include p53 (35, 50), p21^{Cip1/Waf1} (36), p15^{INK4b} (37, 38), p16^{INK4a} (39), vimentin (51), fibronectin (52), PAI (53), and several SASP components (54, 55). Some of these upregulated gene expressions critically control the cell senescence itself, and contributes to the aging process and age-related diseases (56–58). Among the senescence-associated gene products, synthesis and secretion of SASP components have recently been of interest due to their potential link to various age-related diseases (24, 59).

TYPES OF SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE COMPONENTS

The culture medium of senescent cells is enriched with secreted proteins (60, 61). The functional involvement of the secreted proteins in age-associated pathologies was initially recognized in a study by Campisi et al., where the secreted factors from senescent fibroblasts, especially MMP3, promoted the transformation of premalignant mammary epithelial cells (62, 63). This observation confirmed the belief that senescence might act as a tumor suppressor mechanism through the irreversible senescence arrest feature, thus emphasizing its potential to act as a double-edged sword within the tumor microenvironment. In addition, there is accumulating evidence that senescent cells secrete a variety of inflammatory cytokines, chemokines, proteases, and other immune modulators (22). As a result, it is predicted that senescent cells modify the tissue microenvironment *in vivo* by massive alteration of SASP expression (42). Most importantly, studies have revealed that the secretion of SASP components is conserved between human and mouse cells *in vitro* and *in vivo* (22, 23, 64–66), and it commonly occurs in the progress to senescence of various cell types, such as fibroblasts, epithelial cells, endothelial cells, and astrocytes (62, 67–69). Currently, some SASP components are used as general markers of senescence (64). These observations led us to investigate in detail the action mechanisms of SASP components in diverse age-related pathologies.

To thoroughly investigate the possible mechanisms by which SASP contributes to age-related pathologies, we have divided the SASP-related factors into three categories, depending on the mode of action that initiates the SASP activity: receptor-re-

quiring SASP, direct-acting SASP, and SASP regulatory factors.

Receptor-requiring SASP

These factors include cytokines (interleukins), chemokines, and growth factors, which generally initiate their innate functions by binding to their respective receptors on the surface of target cells, and activating receptor-mediated intracellular signal transduction pathways. The most prominent SASP cytokines are interleukin (IL)-6, -8, and -1 α ; their mechanism of action in, and their contributions to cancer, are well understood. IL-6 secretion is markedly augmented in DNA damage and oncogene-induced senescence of mouse and human keratinocytes, melanocytes, monocytes, fibroblasts, and epithelial cells (54, 70, 71). Interestingly, IL-6 expression is upregulated by IL-1 (68, 72), which is also known to be overexpressed and secreted by senescent cells (23); this implies that the SASP component expression may be sequentially regulated in a hierarchical cascade through their autocrine activity. Among the chemokines, GRO α (CXCL-1), GRO β (CXCL-2), MCP-1 (CCL-2), RANTES (CCL5), HCC-4 (CCL-16), eotaxin-3 (CCL-26), and MIP-3 α (CCL-20) are reported to be secreted by senescent cells (64, 73). They exert their biological effects by interacting with their own G protein-linked transmembrane receptors (chemokine receptors). Increased expression of many growth factors such as HGF, FGF, TGF β 1 and GM-CSF, has also been reported in various types of senescent cells (54, 74). The effect of these receptor-requiring SASP components on age-related diseases, including inflammatory diseases and cancer, relies on the target cells that express their respective receptors. The target cell may be the senescent cell itself, thereby aggravating or shielding the cell from senescence progression. Alternatively, the target cells may be various types of normal cells that are nearby; in this case, the cellular environment may be gradually modified to give rise to a pathological condition, or to create an environment in which multiple pathologies may arise.

Direct-acting SASP

Many matrix metalloproteinases (MMPs) belong to this group. MMP family members that are consistently upregulated in human and mouse fibroblasts undergoing replicative or stress-induced senescence include stromelysin-1 and -2 (also called MMP-3 and -10, respectively) and collagenase-1 (MMP-1) (75–77). Another family of proteases that belongs to this SASP category are the serine proteases: urokinase-type or tissue-type plasminogen activators (uPA and tPA, respectively) (78, 79). These direct-acting SASP components exert their proteolytic activities on their respective substrates, mostly extracellular matrix (ECM) proteins, the extracellular portion of membrane-anchoring proteins, or some soluble molecules released from cells, thereby modifying the extracellular microenvironment. Although non-protein small molecules such as ROS, transported ions, and metabolites may also belong to this group, they will not be discussed in this review since they are not proteins.

SASP regulatory factors

Members of this group include TIMPs, PAIs, and IGFBPs. These factors do not have their own enzymatic or signal triggering activities, but modulate the activities of receptor-requiring or direct-acting SASP components by binding to them. The TIMPs comprise of a family of four protease inhibitors: TIMP1, TIMP2, TIMP3, and TIMP4. TIMPs are generally known to inhibit most of the activated MMPs, but in some cases they are known to form complexes with the latent form of MMPs, such as MMP2 and MMP9 (80). The complex of TIMP2 with latent MMP2 (pro-MMP2) serves to facilitate the activation of pro-MMP2 at the cell surface by MT1-MMP (MMP14), a membrane-anchored MMP. The role of the pro-MMP9/TIMP1 complex has yet to be elucidated (80). TIMPs are known to be highly inducible in response to many cytokines and hormones (81), suggesting that their upregulated expression in senescent cells may be the result of the autocrine activity of SASP cytokines.

PAI-1 is a member of the serine protease inhibitor family (serpin); also known as SERPINE1, it functions as the major inhibitor of tPA and uPA, regulating fibrinolysis (the physiological breakdown of blood clots). PAI-1 also blocks the activ-

ity of MMPs, which play a crucial role in the invasion of malignant cells across the basal lamina (82). In addition, physiological roles for PAI-1 in metabolic diseases, such as insulin resistance and cardiovascular disease, have often been reported (83, 84). PAI-2 (SERPINB2) is primarily known to be secreted by the placenta. Recently, it has also been reported to bind to several intracellular and extracellular proteins, and to play a role in the regulation of adaptive immunity (85).

IGFBPs act as carrier proteins for insulin-like growth factor (IGF) and help to maintain the half-life of circulating IGFs in many tissues, thereby modulating IGF signaling depending on the tissue context (86, 87). In humans, IGFBPs are transcribed from seven genes, IGFBP1-7, which share a 50% homology (88). Despite their similarities, the importance of IGF signaling in various pathologies, and the subtle structural differences among the IGFBPs, indicate their tremendous potential roles in modulating age-related diseases.

STAGE-SPECIFIC EXPRESSION OF SASP COMPONENTS IN THE PROGRESS OF SENESCENCE

Senescent cells express only selected SASP components at dif-

Fig. 1. Possible action mechanisms of SASPs, based on differential expression of SASP-related factors.

ferent stages of senescence progression. For example, IL-1 α expression is one of the earliest events after senescent growth arrest, and its autocrine activity induces several second-wave SASP components, including IL-6 and -8, via activation of nuclear factor κ B (NF- κ B) and C/EBP β (72). In cultures, our recent time-series of gene expression profiles during the progression of replicative senescence in human diploid fibroblasts (HDF) supports the idea of stage-specific SASP expression (25). These observations imply that senescent cells at different stages may have varying impacts on the progress of even the same age-related disease, such as cancer.

POSSIBLE ACTION MECHANISMS OF SASP BY DIFFERENTIAL EXPRESSION OF SASP-RELATED FACTORS

As described above, the overall contribution of individual SASP components to the progress of senescence itself or to age-related pathologies does not depend on the expression levels of the SASP component alone; it is also affected by the inhibitory, regulatory, or counteracting SASP molecules coexpressed by the same senescent cell. In addition, expression levels of SASP component receptors on the target cell, which may be the senescent cell itself or nearby cells, are another critical factor. Based on our previous time series of gene expression profiles for all of the SASP-related factors, including SASP components, SASP regulators, and SASP receptors (25), the possible action mechanisms of SASP components can be placed into six groups (Fig. 1).

Expression of direct-acting SASP components alone

Direct-acting SASP proteases (proteinases) can modulate the tissue microenvironment by regulating turnover of the ECM through processing of ECM factors, including collagen, fibronectin, and proteoglycans (Fig. 1A). By ectodomain shedding, they can also regulate the activity of certain growth factors and cytokines such as HB-EGF and TNF- α , and membrane-spanning receptors such as c-Met (89-91).

Expression of SASP component with its receptor

Senescent cells express a diverse array of receptor-requiring

SASP factors. The effect and action mechanisms of these factors can be very different, depending on the cell types expressing their receptors. If a senescent cell expresses both a SASP component and its receptor, then the SASP component will signal to the senescent cell itself via autocrine activity (Fig. 1B). A good example is the increased expression during senescence of both IL-8 and its receptor, IL-8RB (CXCR2), and their involvement in mediating senescence (25, 64). Similar expression patterns for IL-8 and IL-8RB were also observed in our study of replicative senescence in HDF (Table 1).

Expression of SASP component without its receptor

If senescent cells express only a SASP component while suppressing expression of its receptor, then the SASP component will affect nearby non-senescent cells or other target cells expressing its receptor via paracrine activity (Fig. 1C). Similar expression profiles for this group are seen for IL-17 and -20 (25), but their functional relevance to senescence or age-associated diseases has yet to be elucidated.

Regulation of counteracting SASP components

Senescent cells also regulate counteracting SASP components (SASP_C) that block specific SASP-triggered signaling events (Fig. 1D). Anti-inflammatory cytokines such as IL-4, -10, -13, and -35 may act as SASP_C. IL-10 and -13 expression was found to be downregulated during replicative senescence of HDF (25), implying that proinflammatory signaling can be activated in senescence.

Expression of SASP regulatory factors

Senescent cells express regulatory SASP components (SASP_R) that prolong or promote certain SASP-mediated signaling events by binding to their respective receptors or to the SASP component itself (Fig. 1E). Representative examples are the IGFBPs, which are IGF signaling regulators. Insulin/IGF-mediated signaling is known to be a significant contributor to biological aging in many organisms (92, 93). Therefore, it is not surprising that the IGFBPs would have a role in senescence and aging. Increased expression of IGFBPs such as IGFBP2, IGFBP5, and IGFBP7, and their involvement in cell senescence, organismal aging, and age-associated diseases have been reported recently

Table 1. Combined activity of interleukins and expression of their respective receptors*

Names	Expression changes during senescence		Differential action mechanisms	
	Interleukins	Receptors	Young cell	Senescent cell
IL1A, IL1B, IL12 IL17, IL20	Up	Down	High sensitivity	Paracrine action only
IL6, IL8, IL21	Up	Up	Suppressed overall action	Para- & autocrine action
IL13, IL15, IL18	Down	Up	Paracrine action only	High sensitivity
IL3, IL10, IL17	Down	Down	Para- & autocrine action	Loss of overall activity

*This table was created by reanalyzing previously reported results (90).

(54, 94, 95). By contrast, IGFBP6 expression is associated with delayed replicative senescence of HDF (96). Our previous study of gene expression profiles during replicative senescence also demonstrated that IGFBP4 and IGFBP6 were downregulated, whereas IGFBP2, IGFBP3, IGFBP5, and IGFBP7 were upregulated (25), supporting their different contributions to senescence and the aging progress.

Expression of SASP inhibitory factors

The release of inhibitory SASP components (SASP_i) inhibits SASP component activity by direct interactions (Fig. 1F). PAI and TIMP are good examples. Comi et al. proposed that PAI-1 could be used as a senescence marker for endothelial cells (97). However, another study reported that uPA and PAI-1 are constitutively expressed in young, mitotically active cells, whereas tPA and PAI-2 are markedly increased in senescent lung epithelial cells, thus underlining the importance of senescence-associated alterations in tPA activator activity (98). In addition, both MMPs and their inhibitors (TIMPs) are altered during replicative senescence (76). These alterations were further confirmed by the results of our previous study on replicative senescence (Table 2), suggesting that the senescence-associated activities of MMPs and PAs are not just due to the levels of the component itself, but also due to the balance between expression of SASP components and their respective SASP_i.

The above observations and the deduced mechanisms indicate that it is the well-orchestrated activity of all of the SASP components, rather than the activity of a single SASP component, that determines whether a senescent cell will be the source of specific age-related pathologies. Alternatively, this activity may modify the tissue microenvironment so that it is susceptible to age-associated pathologies.

POTENTIAL ROLES OF SENESCENT CELLS IN AGE-ASSOCIATED PATHOLOGIES

Although the molecular mechanisms of the individual SASP components involved in aging and age-associated diseases have been demonstrated, it is still undoubtedly complex and unclear as to how the senescent cells expressing multiple SASP-related factors contribute to these pathologies. When on-

ly the direct-acting SASP components are considered, the contribution of senescent cells to pathology would seem predictable, since the direct-acting SASP components mainly modify the surrounding tissue microenvironment by modulating the ECM. However, their ultimate activities still depend on the levels of coexpressed SASP_i and SASP_r. On the other hand, understanding the role of senescent cells in conjunction with the expression of receptor-requiring SASP components is obviously more difficult. Therefore, we propose below four classes of potential roles for senescent cells in age-associated pathologies. We have used the differential expression profiles of interleukins and their receptors as examples (Table 1 and Fig. 2).

Class I: senescent cells act as effector cells to modulate the microenvironment by releasing SASP components alone

In this class, senescent cells express increased levels of certain SASP components but decreased levels of their respective receptors, whereas young cells express only the receptor. Thus, SASP components released from senescent cells target the young cells or other disease-prone cells, such as cancer cells, which express the SASP receptors, thereby generating a one-sided paracrine communication from the senescent to the young (target) cell. In this scenario, senescent cells act as effector cells by attacking and modulating the surrounding non-senescent cells via release of certain SASP components, eventually contributing to pathogenesis. Based on our previous results (Table 1), IL-1, -2, -12, -17d, and -20 may act in this class.

Class II: senescent cells communicate among themselves by coexpressing SASP components and their respective receptors

When senescent cells, but not the surrounding nonsenescent cells, express both pathogenic SASP components and their receptors, SASP-mediated communication will occur only among senescent cells via both autocrine and paracrine activities. In this scenario, SASP may promote senescence progression or modify senescent cells to acquire pathogenic features (72). If the surrounding nonsenescent disease-prone cells, such as cancer cells, express the receptor, then paracrine communication from the senescent cell to the disease-prone cell may promote pathogenesis. This concept is supported by several recent re-

Table 2. Combined activity of MMPs and their inhibitory factors*

Expression changes during senescence		Possible action mechanisms	
		Young cell	Senescent cell
MMP1, MMP3, MMP12	Up	Combined activity of MMPs (MMP2, MMP11, MMP20, MMP27) and TIMP4	Combined activity of MMPs (MMP1, MMP3, MMP12) and TIMPs (TIMP1, TIMP2, TIMP3)
MMP2, MMP11, MMP20, MMP27	Down		
TIMP1, TIMP2, TIMP3	Up		
TIMP4	Down		

*This table was created by reanalyzing previously reported results (90).

Fig. 2. Potential roles of senescent cells in age-associated pathologies.

ports which show that IL-6 and -8 released from senescent cells promote the epithelial-mesenchymal transition and invasiveness of premalignant epithelial cells in culture (54). Representative SASP components in this class may include IL-6, -8, -21, and -32 (Table 1 and Fig. 2).

Class III: senescent cells act as target cells expressing SASP receptors only

In some cases, senescent cells express high levels of certain SASP receptors alone, without expressing their respective SASP components, whereas nearby young cells express the SASP components. In this scenario, the senescent cell becomes susceptible to these SASP components, probably making itself a target cell by a one-sided paracrine communication from the proliferating young cell to the senescent cell. This class may include IL-7, -13, -15, -18, -19, -23, -25, and -34 (Table 1 and Fig. 2). However, it is unclear whether these SASP components act to promote senescence or to destine the senescent cell to become a source of pathogenesis.

Class IV: senescent cells lose cell-to-cell communication by suppressing expression of SASP components and their respective receptors

If senescent cells suppress the expression of specific SASP components and their receptors, they lose their autocrine and paracrine communication. IL-3, -10, -17a, -17b, and -17c are in this class (Table 1 and Fig. 2). Interestingly, IL-10 is known to act as an anti-inflammatory cytokine and has a protective role against atherosclerosis (99). Therefore, losing IL-10-mediated communication may accelerate other inflammatory responses and result in pathogenic progression.

We have proposed four possible mechanistic contributions of senescent cells to age-associated pathologies by referring only to the differential expression of interleukins and their receptors. However, all four of these scenarios may occur at the same time in the same tissue, suggesting that their orchestrated actions are involved in promoting senescence-associated pathogenic tissue environments and remodeling. Moreover, considering all of the contributions made by the other SASP-related factors, it is challenging to explain the roles of senescence in pathogenesis. Nevertheless, elucidating SASP-mediated extracellular microenvironmental remodeling, in addition to senescence-related intracellular signaling, is crucial in establishing

a correct and complete understanding of senescence and its related pathologies. More detailed studies of the integrity of the SASP-related factors, in terms of the components and their functional interconnections, are needed to develop and exploit appropriate prosenescent or antisenescence therapeutic strategies.

ACKNOWLEDGEMENTS

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (2012R1A5A2048183).

REFERENCES

- Campisi J (2005) Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. *Cell* 120, 513-522
- Dimri GP, Lee X, Basile G et al (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc Natl Acad Sci U S A* 92, 9363-9367
- Hayflick L and Moorhead PS (1961) The serial cultivation of human diploid cell strains. *Exp Cell Res* 25, 585-621
- Martin JA and Buckwalter JA (2001) Roles of articular cartilage aging and chondrocyte senescence in the pathogenesis of osteoarthritis. *Iowa Orthop J* 21, 1-7
- Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H and Komuro I (2002) Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. *Circulation* 105, 1541-1544
- Youdim MB and Riederer P (1993) The role of iron in senescence of dopaminergic neurons in Parkinson's disease. *J Neural Transm Suppl* 40, 57-67
- Castro P, Xia C, Gomez L, Lamb DJ and Ittmann M (2004) Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. *Prostate* 60, 153-159
- Baker DJ, Wijshake T, Tchkonian T et al (2011) Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. *Nature* 479, 232-236
- Aikata H, Takaishi H, Kawakami Y et al (2000) Telomere reduction in human liver tissues with age and chronic inflammation. *Exp Cell Res* 256, 578-582
- Herbig U, Jobling WA, Chen BP, Chen DJ and Sedivy JM (2004) Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). *Mol Cell* 14, 501-513
- d'Adda di Fagagna F, Reaper PM, Clay-Farrace L et al (2003) A DNA damage checkpoint response in telomere-initiated senescence. *Nature* 426, 194-198
- Rodier F, Coppe JP, Patil CK et al (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. *Nat Cell Biol* 11, 973-979
- Braig M and Schmitt CA (2006) Oncogene-induced senescence: putting the brakes on tumor development. *Cancer Res* 66, 2881-2884
- Lee S, Dorken B and Schmitt CA (2004) Extracorporeal photopheresis in graft-versus-host disease: ultraviolet radiation mediates T cell senescence in vivo. *Transplantation* 78, 484-485
- Ewald JA, Desotelle JA, Wilding G and Jarrard DF (2010) Therapy-induced senescence in cancer. *J Natl Cancer Inst* 102, 1536-1546
- Chen QM, Tu VC, Catania J, Burton M, Toussaint O and Dilley T (2000) Involvement of Rb family proteins, focal adhesion proteins and protein synthesis in senescent morphogenesis induced by hydrogen peroxide. *J Cell Sci* 113 (Pt 22), 4087-4097
- Balaban RS, Nemoto S and Finkel T (2005) Mitochondria, oxidants, and aging. *Cell* 120, 483-495
- Passos JF, Nelson G, Wang C et al (2010) Feedback between p21 and reactive oxygen production is necessary for cell senescence. *Mol Syst Biol* 6, 347
- Itahana K, Campisi J and Dimri GP (2007) Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. *Methods Mol Biol* 371, 21-31
- Kuilman T, Michaloglou C, Mooi WJ and Peeper DS (2010) The essence of senescence. *Genes Dev* 24, 2463-2479
- Narita M, Nunez S, Heard E et al (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. *Cell* 113, 703-716
- Freund A, Orjalo AV, Desprez PY and Campisi J (2010) Inflammatory networks during cellular senescence: causes and consequences. *Trends Mol Med* 16, 238-246
- Rodier F and Campisi J (2011) Four faces of cellular senescence. *J Cell Biol* 192, 547-556
- Campisi J, Andersen JK, Kapahi P and Melov S (2011) Cellular senescence: a link between cancer and age-related degenerative disease? *Semin Cancer Biol* 21, 354-359
- Kim YM, Byun HO, Jee BA et al (2013) Implications of time-series gene expression profiles of replicative senescence. *Aging Cell* 12, 622-634
- Cristofalo VJ, Lorenzini A, Allen RG, Torres C and Tresini M (2004) Replicative senescence: a critical review. *Mech Ageing Dev* 125, 827-848
- Greenberg SB, Grove GL and Cristofalo VJ (1977) Cell size in aging monolayer cultures. *In Vitro* 13, 297-300
- Hwang ES, Yoon G and Kang HT (2009) A comparative analysis of the cell biology of senescence and aging. *Cell Mol Life Sci* 66, 2503-2524
- Wang E and Gundersen D (1984) Increased organization of cytoskeleton accompanying the aging of human fibroblasts in vitro. *Exp Cell Res* 154, 191-202
- Cristofalo VJ and Kritchevsky D (1969) Cell size and nucleic acid content in the diploid human cell line WI-38 during aging. *Med Exp Int J Exp Med* 19, 313-320
- Sherwood SW, Rush D, Ellsworth JL and Schimke RT (1988) Defining cellular senescence in IMR-90 cells: a flow cytometric analysis. *Proc Natl Acad Sci U S A* 85, 9086-9090
- Wagner M, Hampel B, Bernhard D, Hala M, Zwerschke W and Jansen-Durr P (2001) Replicative senescence of human endothelial cells in vitro involves G1 arrest, polyploidization and senescence-associated apoptosis. *Exp Gerontol* 36, 1327-1347
- Takahashi A, Ohtani N and Hara E (2007) Irreversibility of

- cellular senescence: dual roles of p16INK4a/Rb-pathway in cell cycle control. *Cell Div* 2, 10
34. Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* 88, 593-602
 35. Kulju KS and Lehman JM (1995) Increased p53 protein associated with aging in human diploid fibroblasts. *Exp Cell Res* 217, 336-345
 36. Chen X, Zhang W, Gao YF, Su XQ and Zhai ZH (2002) Senescence-like changes induced by expression of p21(waf1/Cip1) in NIH3T3 cell line. *Cell Res* 12, 229-233
 37. Malumbres M, Perez De Castro I, Hernandez MI, Jimenez M, Corral T and Pellicer A (2000) Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). *Mol Cell Biol* 20, 2915-2925
 38. He J, Kallin EM, Tsukada Y and Zhang Y (2008) The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b). *Nat Struct Mol Biol* 15, 1169-1175
 39. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D and Barrett JC (1996) Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. *Proc Natl Acad Sci U S A* 93, 13742-13747
 40. Stein GH, Beeson M and Gordon L (1990) Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. *Science* 249, 666-669
 41. Stein GH and Dulic V (1998) Molecular mechanisms for the senescent cell cycle arrest. *J Invest Dermatol Symp Proc* 3, 14-18
 42. Campisi J and d'Adda di Fagagna F (2007) Cellular senescence: when bad things happen to good cells. *Nat Rev Mol Cell Biol* 8, 729-740
 43. Fingar DC, Salama S, Tsou C, Harlow E and Blenis J (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. *Genes Dev* 16, 1472-1487
 44. Mamane Y, Petroulakis E, LeBacquer O and Sonenberg N (2006) mTOR, translation initiation and cancer. *Oncogene* 25, 6416-6422
 45. Yentrapalli R, Azimzadeh O, Sriharshan A et al (2013) The PI3K/Akt/mTOR pathway is implicated in the premature senescence of primary human endothelial cells exposed to chronic radiation. *PLoS One* 8, e70024
 46. Kim YM, Shin HT, Seo YH et al (2010) Sterol regulatory element-binding protein (SREBP)-1-mediated lipogenesis is involved in cell senescence. *J Biol Chem* 285, 29069-29077
 47. Seo YH, Jung HJ, Shin HT et al (2008) Enhanced glycolysis is involved in cellular senescence via GSK3/GS modulation. *Aging Cell* 7, 894-907
 48. De Priest W, Van Manen R and Knook DL (1984) Lysosomal activity in the aging rat liver: II. Morphometry of acid phosphatase positive dense bodies. *Mech Ageing Dev* 26, 205-216
 49. Yoon YS, Yoon DS, Lim IK et al (2006) Formation of elongated giant mitochondria in DFO-induced cellular senescence: involvement of enhanced fusion process through modulation of Fis1. *J Cell Physiol* 209, 468-480
 50. Atadja P, Wong H, Garkavtsev I, Veillette C and Riabowol K (1995) Increased activity of p53 in senescing fibroblasts. *Proc Natl Acad Sci U S A* 92, 8348-8352
 51. Nishio K, Inoue A, Qiao S, Kondo H and Mimura A (2001) Senescence and cytoskeleton: overproduction of vimentin induces senescent-like morphology in human fibroblasts. *Histochem Cell Biol* 116, 321-327
 52. Kumazaki T, Kobayashi M and Mitsui Y (1993) Enhanced expression of fibronectin during in vivo cellular aging of human vascular endothelial cells and skin fibroblasts. *Exp Cell Res* 205, 396-402
 53. Eren M, Boe AE, Murphy SB et al (2014) PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. *Proc Natl Acad Sci U S A* 111, 7090-7095
 54. Coppe JP, Patil CK, Rodier F et al (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. *PLoS Biol* 6, 2853-2868
 55. Vital P, Castro P, Tsang S and Ittmann M (2014) The senescence-associated secretory phenotype promotes benign prostatic hyperplasia. *Am J Pathol* 184, 721-731
 56. Brookes S, Rowe J, Gutierrez Del Arroyo A, Bond J and Peters G (2004) Contribution of p16(INK4a) to replicative senescence of human fibroblasts. *Exp Cell Res* 298, 549-559
 57. Kueper T, Grune T, Prah S et al (2007) Vimentin is the specific target in skin glycation. Structural prerequisites, functional consequences, and role in skin aging. *J Biol Chem* 282, 23427-23436
 58. Salminen A and Kaamiranta K (2010) Glycolysis links p53 function with NF-kappaB signaling: impact on cancer and aging process. *J Cell Physiol* 224, 1-6
 59. Childs BG, Durik M, Baker DJ and van Deursen JM (2015) Cellular senescence in aging and age-related disease: from mechanisms to therapy. *Nat Med* 21, 1424-1435
 60. Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S and Nelson PS (2006) The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. *Cancer Res* 66, 794-802
 61. Wajapeyee N, Serra RW, Zhu X, Mahalingam M and Green MR (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. *Cell* 132, 363-374
 62. Parrinello S, Coppe JP, Krtolica A and Campisi J (2005) Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. *J Cell Sci* 118, 485-496
 63. Krtolica A, Parrinello S, Lockett S, Desprez PY and Campisi J (2001) Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. *Proc Natl Acad Sci U S A* 98, 12072-12077
 64. Acosta JC, O'Loughlin A, Banito A, Raguz S and Gil J (2008) Control of senescence by CXCR2 and its ligands. *Cell Cycle* 7, 2956-2959
 65. Kortlever RM, Higgins PJ and Bernards R (2006) Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. *Nat Cell Biol* 8, 877-884
 66. Kuilman T, Michaloglou C, Vredeveld LC et al (2008)

- Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. *Cell* 133, 1019-1031
67. Salminen A, Ojala J, Kaamiranta K, Haapasalo A, Hiltunen M and Soininen H (2011) Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. *Eur J Neurosci* 34, 3-11
 68. Kumar S, Millis AJ and Baglioni C (1992) Expression of interleukin 1-inducible genes and production of interleukin 1 by aging human fibroblasts. *Proc Natl Acad Sci U S A* 89, 4683-4687
 69. Garfinkel S, Brown S, Wessendorf JH and Maciag T (1994) Post-transcriptional regulation of interleukin 1 alpha in various strains of young and senescent human umbilical vein endothelial cells. *Proc Natl Acad Sci U S A* 91, 1559-1563
 70. Lu SY, Chang KW, Liu CJ et al (2006) Ripe areca nut extract induces G1 phase arrests and senescence-associated phenotypes in normal human oral keratinocyte. *Carcinogenesis* 27, 1273-1284
 71. Sarkar D, Lebedeva IV, Emdad L, Kang DC, Baldwin AS, Jr. and Fisher PB (2004) Human polynucleotide phosphorylase (hPNPaseold-35): a potential link between aging and inflammation. *Cancer Res* 64, 7473-7478
 72. Orjalo AV, Bhaumik D, Gengler BK, Scott GK and Campisi J (2009) Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. *Proc Natl Acad Sci U S A* 106, 17031-17036
 73. Coppe JP, Patil CK, Rodier F et al (2010) A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. *PLoS One* 5, e9188
 74. Acosta JC, Banito A, Wuestefeld T et al (2013) A complex secretory program orchestrated by the inflammasome controls paracrine senescence. *Nat Cell Biol* 15, 978-990
 75. West MD, Pereira-Smith OM and Smith JR (1989) Replicative senescence of human skin fibroblasts correlates with a loss of regulation and overexpression of collagenase activity. *Exp Cell Res* 184, 138-147
 76. Millis AJ, Hoyle M, McCue HM and Martini H (1992) Differential expression of metalloproteinase and tissue inhibitor of metalloproteinase genes in aged human fibroblasts. *Exp Cell Res* 201, 373-379
 77. Zeng G and Millis AJ (1996) Differential regulation of collagenase and stromelysin mRNA in late passage cultures of human fibroblasts. *Exp Cell Res* 222, 150-156
 78. Blasi F and Carmeliet P (2002) uPAR: a versatile signalling orchestrator. *Nat Rev Mol Cell Biol* 3, 932-943
 79. Coppe JP, Desprez PY, Krtolica A and Campisi J (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. *Annu Rev Pathol* 5, 99-118
 80. Brew K, Dinakarpanian D and Nagase H (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. *Biochim Biophys Acta* 1477, 267-283
 81. Reichenstein M, Reich R, LeHoux JG and Hanukoglu I (2004) ACTH induces TIMP-1 expression and inhibits collagenase in adrenal cortex cells. *Mol Cell Endocrinol* 215, 109-114
 82. Binder BR, Christ G, Gruber F et al (2002) Plasminogen activator inhibitor 1: physiological and pathophysiological roles. *News Physiol Sci* 17, 56-61
 83. Alessi MC, Poggi M and Juhan-Vague I (2007) Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. *Curr Opin Lipidol* 18, 240-245
 84. Gils A and Declercq PJ (2004) The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. *Thromb Haemost* 91, 425-437
 85. Schroder WA, Major L and Suhrbier A (2011) The role of SerpinB2 in immunity. *Crit Rev Immunol* 31, 15-30
 86. Hwa V, Oh Y and Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. *Endocr Rev* 20, 761-787
 87. Stewart CE, Bates PC, Calder TA, Woodall SM and Pell JM (1993) Potentiation of insulin-like growth factor-I (IGF-I) activity by an antibody: supportive evidence for enhancement of IGF-I bioavailability in vivo by IGF binding proteins. *Endocrinology* 133, 1462-1465
 88. Clemmons DR, Busby WH, Arai T et al (1995) Role of insulin-like growth factor binding proteins in the control of IGF actions. *Prog Growth Factor Res* 6, 357-366
 89. Chow FL and Fernandez-Patron C (2007) Many membrane proteins undergo ectodomain shedding by proteolytic cleavage. Does one sheddase do the job on all of these proteins? *IUBMB Life* 59, 44-47
 90. Hayashida K, Bartlett AH, Chen Y and Park PW (2010) Molecular and cellular mechanisms of ectodomain shedding. *Anat Rec (Hoboken)* 293, 925-937
 91. Athauda G, Giubellino A, Coleman JA et al (2006) c-Met ectodomain shedding rate correlates with malignant potential. *Clin Cancer Res* 12, 4154-4162
 92. Kenyon C, Chang J, Gensch E, Rudner A and Tabtiang R (1993) A *C. elegans* mutant that lives twice as long as wild type. *Nature* 366, 461-464
 93. Kenyon C (2005) The plasticity of aging: insights from long-lived mutants. *Cell* 120, 449-460
 94. Kojima H, Kunitomo H, Inoue T and Nakajima K (2012) The STAT3-IGFBP5 axis is critical for IL-6/gp130-induced premature senescence in human fibroblasts. *Cell Cycle* 11, 730-739
 95. Chen D, Yoo BK, Santhekadur PK et al (2011) Insulin-like growth factor-binding protein-7 functions as a potential tumor suppressor in hepatocellular carcinoma. *Clin Cancer Res* 17, 6693-6701
 96. Micutkova L, Diener T, Li C et al (2011) Insulin-like growth factor binding protein-6 delays replicative senescence of human fibroblasts. *Mech Ageing Dev* 132, 468-479
 97. Comi P, Chiaramonte R and Maier JA (1995) Senescence-dependent regulation of type 1 plasminogen activator inhibitor in human vascular endothelial cells. *Exp Cell Res* 219, 304-308
 98. West MD, Shay JW, Wright WE and Linskens MH (1996) Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. *Exp Gerontol* 31, 175-193
 99. Han X and Boisvert WA (2015) Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage function. *Thromb Haemost* 113, 505-512